The instrumentation of the
in vitro
culture system has allowed researchers to learn more about the metabolic and growth behavior of
Babesia
spp. The various applications for
in vitro
cultivation of
Babesia
include obtaining attenuated strains for vaccination or pre-munition, the selection of pure lines with different degrees of virulence, studies on biological cloning, ultrastructure, antigen production for diagnostics, drug sensitivity assessments, and different aspects of parasite biology. Although there are different types of vaccines that have been tested against bovine babesiosis, so far, the only procedure that has offered favorable results in terms of protection and safety has been the use of live attenuated vaccines. In countries, such as Australia, Argentina, Brazil, Uruguay and Israel, this type of vaccine has been produced and used. The alternative to live vaccines other than splenectomized calf-derived biological material, has been the
in vitro
cultivation of
Babesia bovis
and
B. bigemina
. The development of
in vitro
culture of
Babesia
spp. strains in a defined medium has been the basis for the initiation of a source of parasites and exoantigens for a variety of studies on the biochemistry and immunology of babesiosis. The use of live immunogens from attenuated strains derived from
in vitro
culture is highlighted, which has been proposed as an alternative to control bovine babesiosis. In several studies performed in Mexico, this type of immunogen applied to susceptible cattle has shown the induction of protection against the experimental heterologous strain challenge with both,
Babesia
-infected blood and animal exposure to confrontations on tick vector-infested farms. The combination of transfection technologies and the
in vitro
culture system as integrated methodologies would eventually give rise to the generation of genetically modified live vaccines. However, a greater challenge faced now by researchers is the large-scale cultivation of
Babesia
parasites for mass production and vaccine distribution.